EFFECTIVENESS OF COMBINED IMMUNOTHERAPY WITH PROPES AND INFLAMAFERTIN IN SELECTIVE DEFICIENCY OF NK AND NKT CELLS IN ADULT PATIENTS WITH GENETIC DEFICIENCY OF THE FOLATE CYCLE

  • Володимир Михайлович Стефанишин Chief physician of the “Vivere” clinic, president of the Association of Neuroimmunologists of Ukraine. “Vivere” neuroimmunology clinic, Kyiv, Ukraine
  • Дмитро Валерійович Мальцев Candidate of medical sciences, associate professor, head of the laboratory of immunology and molecular biology Experimental and Clinical Medicine Institute at the O.O. Bohomolets National Medical University
Keywords: immune-dependent complications, immunoprophylaxis, immunomodulation, cellular immunodeficiency.

Abstract

Backgrounds. The results of preliminary clinical
studies indicate the potential benefit of combined immunotherapy
with Propes and Inflamafertin to compensate
for NK and/or NKT cell deficiency caused by
genetic folate cycle deficiency (GDFC) in children with
autism spectrum disorders.
The aim of the study: to study the effectiveness
of combined immunotherapy with Propes and Inflamafertin
for NK- and/or NKT-cell deficiency in adults
with GDFC.
Materials and methods. In this single-center,
retrospective, controlled, nonrandomized clinical
trial, data from the medical records of 212 adult patients
aged 19 to 50 years with GDFC (study group,
SH) were analyzed. SH patients received Propes at a
dose of 2 ml i/m every other day at night for 3 consecutive
months (45 injections) and Inflamafertin at a
dose of 2 ml i/m every other day at night for 3 consecutive
months, alternating with Propes (45 injections
actions). The control group (CG) consisted of
34 patients of similar age and gender distribution with
HDFC, who did not receive immunotherapy.
Results and their discussion. The number of NK
cells reached the lower limit of normal in 95 of 131 patients
(72% of cases) with an initial deficiency of these
lymphocytes, and the average number of NK cells
in the blood in the SH increased almost twice during
the 3-month course of immunotherapy (p<0.05;
Z<Z0.05), but returned almost to the initial level during
the next 2 months after withdrawal of immunotherapeutic
agents (р>0.05; Z>Z0.05). The number of NKT
cells normalized in 136 of 174 patients (78% of cases)
with an initial deficiency of these cells, and the average
number of NKT cells in the blood in the SH increased
by half during the course of immunotherapy
(p<0.05; Z<Z0.05) and continued to increase during the
next 2 months after withdrawal of immunotropic drugs
(р<0.05; Z<Z0.05). There was a correlation between
immunotherapy and normalization of the number of
NK- (χ2=22.786; OR=11.215; 95%CI=3.534-35.590)
and NKT-cells (χ2=34.238; OR=9.54; 95%CI=4.094-
22.247) in blood with an average connection between
these processes (criterion φ=0.387 and 0.407, respectively;
C=0.361 and 0.377, respectively).
Conclusions. Combined immunotherapy with
Propes and Inflamafertin is an effective strategy for
the treatment of immunodeficiency caused by GDFC
in adult patients.

Published
2022-09-07
How to Cite
Стефанишин, В., & Мальцев, Д. (2022). EFFECTIVENESS OF COMBINED IMMUNOTHERAPY WITH PROPES AND INFLAMAFERTIN IN SELECTIVE DEFICIENCY OF NK AND NKT CELLS IN ADULT PATIENTS WITH GENETIC DEFICIENCY OF THE FOLATE CYCLE. Immunology and Allergy: Science and Practice, (1-2), 13-21. https://doi.org/10.37321/immunology.2022.1-2-02